Differing Clinical Impact of BRCA1 and BRCA2 Mutations in Serous Ovarian Cancer

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2012 Oct 13

PMID 23057551

Citations 38

Authors

Guoyan Liu

Da Yang

Yan Sun

Ilya Shmulevich

Fengxia Xue

Anil K Sood

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

A key function of BRCA1 and BRCA2 is the participation in dsDNAbreak repair via homologous recombination. BRCA1 and BRCA2 mutations, which occur in most hereditary ovarian cancers (OCs) and approximately 10% of all OC cases, are associated with defects in homologous recombination and genomic instability, a phenotype termed 'BRCAness'. The clinical effects of BRCA1 and BRCA2 mutations have commonly been analyzed together; however, it is becoming increasingly apparent that these mutations do not have the same effects in OC. Recently, three major reports highlighted the unequal clinical characteristics of OCs with BRCA1 and BRCA2 mutations. All studies demonstrated that BRCA2-mutated patients are associated with better survival and therapeutic response than BRCA1-mutated and wild-type patients with serous OC. The differing prognostic effects of the BRCA2 and BRCA1 mutations is likely due to differing roles of BRCA1 and BRCA2 in homologous recombination repair and a stronger association between the BRCA2 mutation and a hypermutator phenotype. These new findings have potentially important implications for clinical management of patients with serous OC.

Citing Articles

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.

Pan Y, Hood A, Ahmad H, Altwerger G Ann Pharmacother. 2023; 57(10):1162-1171.

PMID: 36651235 PMC: 11062080. DOI: 10.1177/10600280221149136.

The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.

Vaicekauskaite I, Sabaliauskaite R, Lazutka J, Jarmalaite S Int J Mol Sci. 2022; 23(22).

PMID: 36430148 PMC: 9697406. DOI: 10.3390/ijms232213670.

Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome.

Vicente R, Costa D, Vitorino M, Mendes A, Santos C, Fontes-Sousa M Cancers (Basel). 2022; 14(19).

PMID: 36230639 PMC: 9564125. DOI: 10.3390/cancers14194717.

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.

Tinker A, Altman A, Bernardini M, Ghatage P, Gien L, Provencher D Curr Oncol. 2022; 29(6):4354-4369.

PMID: 35735457 PMC: 9221681. DOI: 10.3390/curroncol29060348.

The current state of molecular profiling in gastrointestinal malignancies.

Mukherji R, Yin C, Hameed R, Alqahtani A, Kulasekaran M, He A Biol Direct. 2022; 17(1):15.

PMID: 35668531 PMC: 9172079. DOI: 10.1186/s13062-022-00322-0.

References

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Wang Z, Li M, Lu S, Zhang Y, Wang H . Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 2006; 5(3):256-60. DOI: 10.4161/cbt.5.3.2380. View

Evers B, Schut E, van der Burg E, Braumuller T, Egan D, Holstege H . A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res. 2009; 16(1):99-108. PMC: 2802735. DOI: 10.1158/1078-0432.CCR-09-2434. View

Lee E, Park S, Park B, Kim S, Lee M, Ahn S . Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 122(1):11-25. DOI: 10.1007/s10549-010-0859-2. View

Liede A, Karlan B, Narod S . Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22(4):735-42. DOI: 10.1200/JCO.2004.05.055. View

Ayoub N, Rajendra E, Su X, Jeyasekharan A, Mahen R, Venkitaraman A . The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry. Curr Biol. 2009; 19(13):1075-85. PMC: 2719694. DOI: 10.1016/j.cub.2009.05.057. View

Artioli G, Borgato L, Cappetta A, Wabersich J, Mocellin S, Dalla Palma M . Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series. Eur J Gynaecol Oncol. 2011; 31(6):658-61. View

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

Yarden R, Pardo-Reoyo S, Sgagias M, Cowan K, Brody L . BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet. 2002; 30(3):285-9. DOI: 10.1038/ng837. View

10.

Joukov V, Groen A, Prokhorova T, Gerson R, White E, Rodriguez A . The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell. 2006; 127(3):539-52. DOI: 10.1016/j.cell.2006.08.053. View

11.

Gilks C, Prat J . Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009; 40(9):1213-23. DOI: 10.1016/j.humpath.2009.04.017. View

12.

Issaeva N, Thomas H, Djureinovic T, Djurenovic T, Jaspers J, Stoimenov I . 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 2010; 70(15):6268-76. PMC: 2913123. DOI: 10.1158/0008-5472.CAN-09-3416. View

13.

Reitsma W, de Bock G, Oosterwijk J, ten Hoor K, Hollema H, Mourits M . Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?. Int J Gynecol Cancer. 2012; 22(4):579-85. DOI: 10.1097/IGC.0b013e31823d1b5c. View

14.

Ben david Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck B, Beller U . Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002; 20(2):463-6. DOI: 10.1200/JCO.2002.20.2.463. View

15.

Liu G, Zhang W . Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?. Chin J Cancer. 2011; 31(1):1-4. PMC: 3777467. DOI: 10.5732/cjc.011.10432. View

16.

Turner N, Lord C, Iorns E, Brough R, Swift S, Elliott R . A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27(9):1368-77. PMC: 2374839. DOI: 10.1038/emboj.2008.61. View

17.

Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M . CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005; 434(7033):598-604. DOI: 10.1038/nature03404. View

18.

Ramus S, Fishman A, Pharoah P, Yarkoni S, Altaras M, Ponder B . Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol. 2001; 27(3):278-81. DOI: 10.1053/ejso.2000.1097. View

19.

Hilton J, Geisler J, Rathe J, DeYoung B, Buller R . Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002; 94(18):1396-406. DOI: 10.1093/jnci/94.18.1396. View

20.

Chen S, Parmigiani G . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-33. PMC: 2267287. DOI: 10.1200/JCO.2006.09.1066. View